New Canadian Regulations Require Disclosure of E-Cigarette Ingredients and Sales Information

Jul.20.2022
New Canadian regulations will require e-cigarette manufacturers to disclose health information about their products' sales and ingredients.

According to reports, Canada is currently developing a new regulation that would require e-cigarette manufacturers to provide health information regarding sales and ingredients.


Currently, the Canadian Department of Health has limited information regarding the sale and composition of electronic cigarette products, making it difficult to adequately track market trends. To address this issue, Carolyn Bennett, Minister of Health and Deputy Minister of Mental Health and Addictions, has announced a 45-day public consultation period to gather information for the development of new regulations for electronic cigarette products. This will require manufacturers to disclose information regarding their sales and ingredients to the Department of Health, in an effort to maintain market transparency and keep pace with the rapidly growing electronic cigarette market in Canada.


Carolyn Bennett stated, "As the electronic cigarette market continues to rapidly grow, many Canadians, including young people, are beginning to use these products. We are taking action to gain a more comprehensive understanding of the health impacts of these products in order to better protect everyone.


This article contains excerpts or reproductions of content from third-party sources whose copyrights belong to the original media and authors. If there is any infringement, please contact us for deletion. Any organization or individual wishing to reprint must contact the author and refrain from direct reproduction.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
Product | BAT Launches VELO WRKS Nicotine Pouches in Sweden, Introducing Dual-Compartment Cans With Two Flavours
Product | BAT Launches VELO WRKS Nicotine Pouches in Sweden, Introducing Dual-Compartment Cans With Two Flavours
British American Tobacco (BAT)'s VELO brand launched the VELO WRKS nicotine pouch range in Sweden on November 2, 2026. The initial release features three Dual Can variants, each containing two separate flavours in a dual-compartment container. Each can holds 20 slim pouches with 8mg of nicotine per pouch and retails for SEK 52.99. According to VELO, the first release, Drop 1, is limited to 75,000 cans and will remain available until February 2027 or while stocks last. VELO positions WRKS as a platform for testing new product concepts and has introduced an online consumer feedback survey. EU trademark records show BAT applied to register VELO WRKS in March 2026 under Class 34, covering nicotine pouches, e-cigarettes, heated tobacco products and other tobacco-related goods.
product
Nov.03
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
Special Report|RLX Technology Consolidates European Distribution Business for First Time: Q3 2026 Revenue Rises Nearly 70%, Gross Margin Falls to 23.3%
Special Report|RLX Technology Consolidates European Distribution Business for First Time: Q3 2026 Revenue Rises Nearly 70%, Gross Margin Falls to 23.3%
RLX Technology reported a 69.7% year-on-year increase in third-quarter 2026 revenue to RMB1.92 billion ($285.9 million), driven primarily by the consolidation of a newly acquired Western European distributor. International markets accounted for 86.5% of revenue. The acquisition followed RLX's RMB744 million purchase of controlling interests in UK vaping company Totally Wicked in 2025, expanding the group's directly controlled European retail and distribution operations. SEC filings also show that purchases from Shenzhen Smoore Technology Limited declined from 80% of RLX's total purchases in 2022 to 23% in 2025. Third-quarter gross margin fell to 23.3%, while GAAP operating income declined 57.7%.
Business
Nov.20
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
Product|AIR Files U.S. PMTA for Crown Switch. Can Greentank's Chip Technology Deliver a Compliance and Competitive Advantage?
AIR Global PLC (NASDAQ: AIIR) announced on November 5, 2026, that it had submitted a Premarket Tobacco Product Application (PMTA) to the U.S. Food and Drug Administration (FDA) for Crown Switch, its rechargeable pod vape platform. First launched in Germany in November 2025, the device uses Quantum Chip atomization technology developed by Canadian vaporization technology company Greentank Innovations. German retail versions feature 2mL prefilled pods containing 18mg/mL nicotine in six flavors, while AIR has separately tested two 5% nicotine formulations intended for U.S. development. AIR invested $20 million in Greentank in July and reported approximately $3.4 million in U.S. PMTA-related regulatory costs for the first nine months of 2026. The Crown Switch application has been submitted, but the FDA has not granted marketing authorization.
product
Nov.13
South Korea's Synthetic Nicotine Tax Take Estimated at Just 1.3% of Forecast as Imports Plunge Nearly 97%
South Korea's Synthetic Nicotine Tax Take Estimated at Just 1.3% of Forecast as Imports Plunge Nearly 97%
After synthetic nicotine was placed under tobacco regulation on April 24, 2026, South Korea’s tax collections from synthetic-nicotine vaping products fell far short of government projections. The Chosun Ilbo reported on November 18 that Ministry of Health and Welfare data showed national health promotion charges on synthetic-nicotine liquid e-cigarettes totaled 765 million won from April 24 through September. Using statutory rates, the newspaper estimated combined major taxes and charges at about 2.622 billion won—on a monthly basis roughly 1.3% of an earlier forecast after temporary tax reductions. Customs data showed synthetic-nicotine imports dropped from about 1,467 metric tons in January–April to 45 metric tons in May–August, a nearly 97% decline. Imports of nicotine-analog and nicotine-free liquids totaled 151 metric tons in May–August, exceeding synthetic-nicotine imports in the same period, though both categories were also below January–April volumes.
Regulations
Nov.19